Stevanato S p A : Sustainability Report 2025

Published: 2026-04-27 05:15:12 ET STVN

Published on 04/27/2026 at 05:15 am EDT

Stevanato Group Sustainability Economic Value Innovation Human Capital Supply Chain Environment Local Communities

Letter to Stakeholders. 4

Methodological Note. 5

Stevanato Group. 7

• At a Glance. 7

• Organizational Details. 9

• Mission, Vision, and Values. 14

• Company Structure and Main Corporate Functions. 15

• Ethics, Integrity, and Compliance. 16

Sustainability. 18

• Approach to Sustainability. 18

• Certifications and Awards. 21

• Participation in Organizations and Associations. 23

Economic Value Creation. 24

• Stakeholder Value Creation. 24

Innovation and Product Responsibility. 25

• Stevanato Group Products, Technologies, and Services. 25

• Biopharmaceutical and Diagnostic Solutions. 26

• Engineering. 28

• Research & Development and Innovation. 29

• R&D for Drug Containment Solutions (DCS). 30

• R&D for Drug Delivery Systems (DDS). 31

• R&D for Engineering. 33

• Analytical Services. 37

• Product Quality and Responsibility. 38

Human Capital. 39

• Stevanato Group's Human Resources. 39

• Employee Management and Development. 42

• Occupational Health & Safety. 46

Supply Chain and Procurement. 48

• Responsible Supply Chain & Procurement. 48

Stevanato Group Sustainability Economic Value Innovation Human Capital Supply Chain Environment Local Communities

Environment. 51

• Stevanato Group's Commitment to the Environment. 51

• Energy Consumption and GHG Emissions. 51

• Water Management. 55

• Waste Management. 57

Local Communities. 59

• Local Communities Engagement. 59

Annex. 61

GRI Content Index. 64

Independent Audit Report. 70

Stevanato Group Sustainability Economic Value Innovation Human Capital Supply Chain Environment Local Communities

Over our 75-year history, we have earned a reputation for high quality and reliability that has enabled us to become a partner of choice for more than 700 companies globally.

We have secured a leadership position within the drug product development and delivery value chain through our investment in research and development and the expansion of our global footprint and capabilities.

Our priority is to provide flexible solutions that preserve the integrity of pharmaceutical products and enable our customers to deliver safe and effective treatments to patients while reducing time to market, total cost of ownership and supply chain risk. We achieve this by developing our products and solutions in close collaboration with our customers, leveraging our scientific research capabilities, technical expertise, and engineering and manufacturing excellence to meet the quality and performance requirements of pharmaceutical and biotech customers.

Since our founding, the delivery of innovation has been a fundamental characteristic of our Group, and we embed science and technology in what we do every day to bring life-changing medicines to patients.

Our goal is to be the global partner of choice to biopharma customers for the full spectrum of end-to-end solutions, from drug development through life-cycle management. We operate in attractive, growing end markets with favorable secular tailwinds. Innovation across the industry continues to advance patient care and we remain mission critical to the delivery of innovative biologics. Biologics are expected to remain our fastest growing end market and

a key driver to top-line growth and margin expansion as we continue to move up the value chain. In Latina and Fishers, we expect to increasingly benefit from improved utilization, efficiencies, and operating leverage, as we support our customers with quality and reliability.

Notwithstanding a dynamic and uncertain political and economic context, we keep to support our stakeholders and we are committed to embedding sustainability in our strategic plan, policies and practices.

To accomplish this, we have a sustainability strategy structured in three pillars:

Sustainable processes and products;

Sustainable value chain;

People and governance.

The main goal is to pursue a regenerative business innovation journey while asserting our position as an interdependent and responsible member of the community in line with the United Nations' Sustainable Development Goals.

In 2025, we progressed in our regenerative business innovation journey as shown in such Sustainability Report on a voluntary basis. With regard to the environment, we progressed in our plan and measurement including Scope 3 in alignment with Science-Based Target initiative and its reduction targets. According to such GHG emissions reduction plan, we progressed mainly in respect to efficiency-related initiatives and sourcing of renewables-based electricity.

In addition, we improved our waste management practices with an increase in the amount of waste recovered and diverted from landfills. With regard to the people we aim to foster a workplace of Merit, Inclusion & Belonging, we improved in our gender balance program on females holding senior positions. With reference to the Governance area, we strengthened and further improved our sustainable corporate model.

Stevanato Group Sustainability Economic Value Innovation Human Capital Supply Chain Environment Local Communities

With regard to Ratings, we significantly improved our disclosure with an overall Best-in-Class positioning among peers. On Ecovadis, we've been awarded with Silver Medal and score 75/100 placing us among the top 15% of all companies assessed. On S&P's CSA, we are in leading position, as well as in Carbon Disclosure Project (CDP).

We confirm our goal is to continue growing and supporting customers throughout our regenerative business innovation while making a positive impact everywhere we work and do business. We are continuously working to improve processes, to innovate on technologies and eco-designed products & packaging, and sustainable solutions. Our team is dedicated

to delivering on our promise by working collaboratively to drive continuous improvement, acting as an example of our Values and Guiding Principles. Therefore, we are pursuing this important journey with confidence and determination toward an increasingly sustainable and responsible future.

Franco Stevanato, Chairman and CEO

Stevanato Group S.p.A. Via Molinella 17, 35017 Piombino Dese · Padova · Italy

This Sustainability Report clearly outlines Stevanato Group's environmental, social, and economic achievements in a transparent and structured manner for the 2025 financial year (January 1-December 31) and aligned with the Company's financial reporting, and it shows the commitment and initiatives undertaken by the Group toward its goal of sustainable development. The annual reporting cycle provides internal and external stakeholders with a summary of Stevanato Group's business performance, results, and impacts in relation to material sustainability in the 2025 financial year.

This document represents the Sustainability Report of the companies belonging to Stevanato Group S.p.A. and its subsidiaries (hereinafter also referred to as "the Company," "Stevanato," the "Stevanato Group," or "the Group"). The list of entities is aligned with the 2025 Annual

20-F Filing. The Sustainability Report includes data about the parent company, Stevanato Group S.p.A., and its subsidiaries, which are directly or indirectly consolidated on a line-by-line basis. Note that for some of Group's commercial entities/sites, only part of the data has been included in the environmental, health, and safety data due to the limited scope1.

Stevanato Group reports sustainability information with reference to the Global Reporting Initiative (GRI) Standards 2021. For more details on the GRI Standards, please see the "GRI Content Index" section. The contents of the Sustainability Report were selected based on the results of a materiality analysis published in this document and described in Chapter 2.

1 Limitation of scope with part of the data for Stevanato Group International a.s., Ompi of Japan Co., Ltd., Medirio SA, and Stevanato Group India Private Limited. The main environmental data for such entities are included.

Stevanato Group Sustainability Economic Value Innovation Human Capital Supply Chain Environment Local Communities

The discussion of materiality in connection with the sustainability material assessment is not an indication that such information or topics are necessarily material under U.S. federal securities laws or the rules and regulations of the U.S. Securities and Exchange Commission (SEC).

Quality criteria and reporting scope information were defined according to GRI principles and encompassed positive and negative impacts, comparability, accuracy, timeliness, clarity, and verifiability. Specifically, the information included in this report was taken from both the Group's IT system and the sustainability reporting package.

To properly manage the reporting process, a Sustainability Reporting Procedure was established in 2021 and updated in 2025, in line with GRI Standards 2021, which illustrates how to prepare the Group's Sustainability Report, including the timing, tools, roles, and responsibilities of the functions and individuals. To ensure responsiveness and proper application of the procedure, the reporting process was extensively discussed and agreed upon by the working group.

The information presented in this report refers to 2025 and includes a comparison with the previous year. Any information restated from previous reporting periods is indicated appropriately, where necessary, throughout the report. The information collected and reported is based on measurable data. To provide an accurate overview of the Group's

performance and help ensure data reliability, the use of estimates has been limited as much as possible. If they are provided, they have been made using the best methods available and are properly identified. This report presents both positive and negative aspects equally, with a comment on the results when appropriate.

This report was approved by the Board of Directors of Stevanato Group S.p.A. in April of 2026. The process of seeking external assurance involved a preliminary evaluation based on different providers and relative core competencies and resulted in the selection and approval of PricewaterhouseCoopers Business Services S.r.l. as an external auditor.

Stevanato Group commissioned this external auditor to provide a limited assurance report, "limited assurance engagement," in accordance with the criteria in the ISAE 3000 Revised Standard, which is attached at the end of this document. It contains a description of what has been assured and on what basis, including the assurance standard used, the level of assurance obtained, any limitations of the assurance process, and the relationships between the organization and the assurance provider.

For further information and suggestions regarding Stevanato Group's Sustainability Report, please contact:

[email protected].

Stevanato Group presents its inclusion and belonging data and policies in accordance with the GRI Standards. Stevanato is aware of US Executive Order 14173 (the "EO") signed in January 2025, under which the U.S. Office of Federal Contract Compliance Programs must, among other things, immediately cease promoting diversity and allowing or encouraging U.S. federal contractors and subcontractors to engage in workforce balancing based on race, color, sex, sexual preference, religion, or national origin. As a foreign private issuer listed on the New York Stock Exchange (NYSE), Stevanato continues to review the implications of the EO.

Our Inclusion & Belonging policies will not apply to Stevanato's U.S. employees to the extent that this would conflict with the EO or other applicable laws, regulations, or orders.

Stevanato Group Sustainability Economic Value Innovation Human Capital Supply Chain Environment Local Communities‌

Stevanato Group Sustainability Economic Value Innovation Human Capital Supply Chain Environment Local Communities

Stevanato Group S.p.A., an Italian multinational company, is a leading global supplier of drug containment, delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries.

Headquartered in Piombino Dese (Padua, Italy), Stevanato Group is a joint stock company. For further information about the Stevanato Group's ownership structure, see item 7.A. "Major Shareholders" in the 2025 Annual

20-F Filing.

In 1949, Giovanni Stevanato founded Soffieria Stella, a specialty glass manufacturer in Zelarino, near Venice. Soffieria Stella, the precursor to Stevanato Group, operated until 1959, when Stevanato Group was established in Piombino Dese (Padua). For more than 75 years, Stevanato Group has evolved from an Italian glassware manufacturer to a leading global provider of integrated solutions for the healthcare industry.

Stevanato Group delivers an integrated end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle at each of

the development, clinical, and commercial stages.

The chart above illustrates Stevanato Group's presence across the pharmaceutical chain, with its impacts along the value chain marked with the symbol "SG."

Stevanato Group Sustainability Economic Value Innovation Human Capital Supply Chain Environment Local Communities

The chart to the right shows our integrated solutions for pharma and healthcare. One of Stevanato Group's main priorities is to provide flexible solutions that preserve the integrity of pharmaceutical products and enable customers to deliver safe and effective treatments to patients while reducing time to market, total cost of ownership and supply chain risk.

Stevanato Group achieves this by developing products in collaboration with customers and leveraging its scientific research capabilities, technical expertise, engineering, and manufacturing excellence to meet its quality requirements.

Stevanato Group divides its market into two categories: direct markets and end markets. Direct markets include products or product categories in which Stevanato directly participates, such as Drug Containment Solutions (DCS).

The Group's end markets include broader sectors, such as biologics, where Stevanato sees demand for its products and services. For further information about Stevanato Group's value chain, see item 4. "Information on the Company" and section b. of the "Business Overview" in the 2025 Annual 20-F Filing.

Stevanato Group has forged many business relationships from collaborations on the development of new technologies and products. For insights into the most relevant business relationships, please visit Press Releases - Stevanato Group.

Stevanato Group Sustainability Economic Value Innovation Human Capital Supply Chain Environment Local Communities

Direct Markets

Stevanato Group operates in the following segments:

Business Segment

Biopharmaceutical and Diagnostic Solutions Engineering

Direct Market

Drug Containment Solutions Drug Delivery Systems

In-Vitro Diagnostic Solutions Engineering

End Market

Biologics Vaccines Insulin

Small Molecules & Generics Molecular Diagnostics Other

Stevanato Group Sustainability Economic Value Innovation Human Capital Supply Chain Environment Local Communities

The Group is a global company with locations in many countries and continents. Stevanato Group's global presence, together with proprietary standardized manufacturing systems and processes, allows the Group to provide consistent product and service standards to its customers around the world. For a more detailed overview of the countries in which the Group's subsidiaries operate, see the "Scope of Consolidation" section of the 2025 Annual 20-F Filing. To read our story, visit Stevanato's corporate website: Our Heritage - Stevanato Group.

Stevanato Group Sustainability Economic Value Innovation Human Capital Supply Chain Environment Local Communities

Stevanato Group's Vision, Mission, and Values provide a framework to guide the Company's pursuit of business goals with an ethical and transparent mindset and focus on fostering innovation.

Mission

We cooperate deeply with our partners all over the world, providing our know-how, resources, and enthusiasm to turn every project into an achievement.

Vision

Create a reliable ecosystem to empower our partners and their ability to produce safe, easy-to-use, and cost-effective treatments to improve patients' lives.

Values

Our vision is based on five core values that are linked together to ensure harmonious interaction. Together, they provide the foundation for leadership rooted in excellence.

Guiding Principles

The adoption of the Guiding Principles leads the Group toward achieving its mission.

Environmental, Social, and Governance (ESG) & Sustainability

Stevanato Group strives to support our stakeholders while making a positive impact for the benefit of all, including society and the planet. At Stevanato Group, our employees understand that, as leaders in the pharmaceutical industry, we maintain a responsibility to implement sustainable and socially responsible practices in the places where we live and work.

Stevanato Group Sustainability Economic Value Innovation Human Capital Supply Chain Environment Local Communities

Sergio Stevanato

Chairman of the Board Emeritus

Franco Stevanato

Executive Chairman and Chief Executive Officer

Madhavan Balachandran

Independent Director

Fabrizio Bonanni

Independent Director

William John Federici

Independent Director

Karen Anne Flynn

Independent Director

Sue-Jean Lin

Independent Director

Elisabetta Magistretti

Independent Director

Donald Eugene Morel Jr.

Independent Director

Luciano Santel

Independent Director

Alvise Spinazzi

Director

The composition of the Group, including its parent company, Stevanato Group S.p.A. and subsidiaries, is described in section C. Organizational Structure - item 4. "Information on the Company" of the 2025 Annual

20-F Filing.

Stevanato Group has adopted a corporate governance standard that sets the rules for the appropriate management of the Group, separating ownership from operating activities. The Group is led by an experienced, highly motivated Board increasing objectivity and independence, and an executive team with a proven track record of operational excellence. The Board meets at least four times per year to make key decisions on specific topics. With regard to the composition of the Board of Directors, it is important to note that eight members are independent directors. As of December 31, 2025, the Board of Directors was composed as follows.

Stevanato Group S.p.A. adopted a one-tier corporate governance system that includes a Board of Directors and an Audit Committee. The Audit Committee complies with the applicable rules and regulations of the SEC and the NYSE corporate governance rules, as well as all Italian law requirements with respect to its composition, expertise

requisites, functioning, and independence.

A more detailed analysis of the governance structure indicates that four committees are made up of Board members tasked with certain roles and responsibilities, as defined in their respective charters. Thus, in addition to the Audit Committee, there are the following

three committees: the Nominating and Corporate Governance Committee, the Business & Strategy Committee, and the Compensation Committee. The members of the different committees described in this document share the same term of office with the

Board of Directors and provide insight and suggestions without prejudice to the Board's competence and decision-making responsibility. In addition, one of the objectives of the Audit Committee is to assist the Board in supporting Stevanato Group's ongoing commitment to issues relating to environmental, social, and governance (ESG) matters. For a complete overview of the features and duties of each committee, please refer to item 6. "Directors, Senior Management, and Employees" of the Company's 2025 Annual 20-F Filing.

As of December 31, 2025, all members of the Board of Directors were over the age of 50 years, while 73% were males and 27% were females.

Board of Directors on 12.31.2025

Role

Stevanato Group Sustainability Economic Value Innovation Human Capital Supply Chain Environment Local Communities

The Company's main corporate and business functions represent a significant investment for Stevanato Group and are essential to its operations and strategy. The purpose of the Group is to create long-term value through our facilities, which are located across all major regions worldwide, with the organization structured by business units to better address the specific

needs of our customers, as reported in the Company chart (update: December, 2025), which is available in the ESG section of the corporate website.

To maintain a sustainable, transparent corporate model, high ethical conduct standards and a culture of ethical behavior and integrity have been adopted.

These are essential for business success and indispensable assets in terms of the Company's reputation. The Group is committed to embedding sustainability values into its policies and practices.

The documents, corporate policy, and statements described below define Stevanato Group's main commitments to responsible business conduct. Please note that all disclosed documents have been approved by Stevanato Group's Board of Directors and are available on the corporate website.

The Code of Ethics defines the guidelines and criteria of conduct for all recipients and aims to ensure compliance with regulations in force to prevent improper acts or behavior and to help protect the legitimate interests of customers, employees, shareholders, business and financial partners, communities, and stakeholder groups.

The Code of Ethics has been disseminated in all of Stevanato Group's companies.

The provisions of the Code of Ethics have been reported via specific internal policies and procedures that ensure compliance with the principles and guidelines of the Code of Ethics.

Stevanato Group Sustainability Economic Value Innovation Human Capital Supply Chain Environment Local Communities

For further details on the Code of Ethics and other policies, please refer to the following links:

Code of Ethics

Anti-Bribery and Anti-Corruption Policy

Related Party Transactions Policy

Anti-Discrimination Policy

Whistleblowing Policy

Supplier Code of Conduct

The Code of Ethics and the Anti-Discrimination Policy cover internationally recognized human rights that are disclosed directly throughout the documentation.

In 2025, all the above-mentioned policies were confirmed by the Board of Directors, including any changes from the previous year. Stevanato Group complies with all applicable laws and regulations to protect its rights and interests. In 2025, no significant instances of

non-compliance with laws and regulations were registered.

Stevanato Group maintains a whistleblowing procedure to manage the reporting of violations and irregularities concerning the Code of Ethics. The whistleblowing procedure was updated, and a new platform was implemented according to EU Directive 2019/1937. As of December 31, 2025, no incidents of corruption had been reported through the Whistleblowing Platform. With regard to human rights, three complaints related to alleged discrimination were ongoing in 2025 in the U.S.; the Company continues to take all appropriate actions with regard to these complaints.

The Italian entities in the Group (i.e., Stevanato Group S.p.A., Nuova Ompi S.r.l., and Spami S.r.l.) have an Organizational, Management, and Control model pursuant to Legislative Decree No. 231/01.

The above-mentioned Italian companies in the Group proceeded with the renewal of the Supervisory Body, which will expire in 2026, pursuant to the aforementioned Legislative Decree responsible for monitoring compliance and operating and updating the model.

According to internal procedures, if reports concerning Legislative Decree 231/01 are received through the Whistleblowing Platform, the Whistleblowing Committee promptly informs the Supervisory Body. For its foreign companies, the Group is currently working to strengthen management systems to ensure compliance with local laws in consideration of the provisions of the Model of Organization, Management, and Control 231.

Regarding business relationships, Stevanato Group has established a Supplier Code of Conduct that is shared with its suppliers. For more information, see section "6.1 Responsible Supply Chain & Procurement."

In 2025, no reports and/or complaints were received regarding non-compliance with laws or regulations or legal action taken regarding anti-competitive behavior, anti-trust, or monopoly violations either in or out of court.

For an overview of Stevanato Group's risk management, see item 3.D. "Risk Factors" of the

2025 Annual 20-F Filing.

Stevanato Group Sustainability Economic Value Innovation Human Capital Supply Chain Environment Local Communities‌

Stevanato Group aims to ensure its long-term success based on its ability to respond to trends and risks related to

Environmental, Social and Governance (ESG) matters that make up the complex context in which the Group operates.

Sustainability is a primary means to improve such opportunity and risk management, while fostering higher efficiency,

cutting-edge innovation and strategic decisions on technologies, products, processes and value chain definition.

Stevanato Group pursues a sustainable development journey as per its materiality analysis which is aligned with the United Nations' Sustainable Development Goals.

The Company seeks to create a regenerative business innovation model while remaining an interdependent and responsible member of the community.

To address ESG trends and risks, Stevanato Group developed a sustainability strategy structured

in three pillars:

Sustainable processes and products, to minimize any potential negative environmental impacts;

Sustainable value chain, to collaborate with partners on improving societal and environmental impacts;

People and governance, to establish and maintain a sustainable and transparent corporate model.

To help safeguard the environment, Stevanato Group progressed further in GHG emissions reduction plan, included Scope 3 GHG emissions, in line with the Science

Based Targets initiative and its target. Main contribution it is in respect to efficiency-related initiatives and sourcing of renewables-based electricity. In addition, the Group took action aligned with climate science and has committed

to set near-term emissions reductions in line with the Science-Based Target initiative to reduce GHG emissions according to its trajectory and respective targets.

Furthermore, Stevanato Group has progressed in waste management with a greater quota of waste recovered with second life applications.

As part of its corporate sustainability and circular innovation measures, Stevanato continued to analyze selected products and packaging from a life cycle perspective while advancing eco-design solutions to reduce, reuse, replace, and recycle while engaging also with suppliers and partners along the value chain.

Stevanato Group has also introduced new sustainability practices as part of its corporate sustainability and circular innovation measures, with a particular emphasis on

Stevanato Group Sustainability Economic Value Innovation Human Capital Supply Chain Environment Local Communities

identifying alternative materials, renewable-based energy, and innovative processes that provide more sustainable solutions. As part of its corporate sustainability and circular innovation measures, Stevanato Group dialogued with customers on a sustainable version of secondary packaging for syringes, focusing on biopolymers and recycled plastic as well as packaging and process improvements to reduce related emissions and other sustainable measures.

With regard to the people we aim to foster a workplace of Merit, Inclusion & Belonging, we improved in our gender balance program on females holding senior positions. Finally, with reference to the Governance area, we strengthened and further improved our sustainable corporate model with regular measures of impacts using the GRI Standards as a framework for transparency

and accountability.

The management of sustainability is distributed across the Stevanato Group through dedicated ESG-related committees at both Board and Management levels, with the Head of ESG leading the whole process since the beginning as head of the ESG & Sustainability function, coordinating efforts of functions and sites across the Group.

Stevanato Group conducted a Materiality Analysis process in accordance with the requirements of GRI Standards 3:2021 to identify the material topics that represent the

most significant impacts on the economy, environment, and people, including impacts on their human rights.

Such Materiality Analysis was approved by Board of Directors as reported in Methodological Note.

The process of determining material topics was informed by the organization's ongoing identification and assessment of impacts.

In particular, the process of defining material topics followed four steps:

Understanding the organization's context through scenario and benchmarking analysis of the main potential ESG trends, risks and opportunities;

Identifying actual and potential, positive or negative impacts, starting from the previous context and benchmarking analysis;

Assessing the significance of the impacts;

Prioritizing the most significant impacts grouped into topics.

Each impact was assessed and rated on a significance dimension, and the weighted average of grouped impacts on topics was used to calculate a comprehensive score for each topic. The resulting most relevant topics above a given threshold, in line with the context and sustainability strategy of Stevanato Group, are:

Product quality and responsibility

Research & Development and innovation

GHG emissions

Energy consumption

Occupational Health & Safety

Business ethics, governance and compliance

Human capital management and development

Economic performance and value creation

Responsible supply chain and procurement

Waste management

Employee well-being

Human rights

Water management

Local communities' engagement

The Group's 2025 Sustainability Report was prepared based on a structured reporting practices formalized by the Sustainability Reporting Procedure according to GRI Standards 2021. It defines and outlines how the

Group's Sustainability Report should be prepared at the operational level in line with the Sustainability Reporting Guidelines issued by GRI.

Such procedure includes the timing, tools, roles and responsibilities of the functions and individuals' roles in the working group (approximately 100 individuals across the Group). It also ensures the engagement and proper application of all procedures. Finally, it is important to note that the process required correct and compliant GRI Key Performance Indicators (KPIs) associated with the functions involved and was coordinated by the Process Owner, as assigned by the Board of Directors.

Stevanato Group Sustainability Economic Value Innovation Human Capital Supply Chain Environment Local Communities

Employees

Suppliers

Customers

Community and local authority

Universities and research centers

Regulators and authorities

Shareholders and Board of Directors

Projects and/or initiatives for company welfare

Company Intranet

Internal newsletter

Insertion schemes for new employees

Company meetings to discuss results and future objectives

Training programs

Round table discussions with unions

Regular meetings

Quality assessment audits/visit

Regular meetings

Surveys/market research

Continuous dialogue through communication channels

Company website

Participation at trade fairs

Projects to support social initiatives

Meetings with representatives of local institutions

Site visits

Partnerships with key universities and schools in Italy and abroad

Discussion meetings with representatives of institutions

Meetings organized throughout the year

The Group has adopted flexible and diversified practices to share present and future Group development strategies with its main stakeholders, that were identified based

on an industry benchmark. Stevanato Group adopts practices that encourage dialogue and involvement with all stakeholder categories, as engagement is considered an essential element of the Group's sustainability strategy and is directly correlated with the Group's medium and long-term success.

The main channels of dialogue and interaction are summarized in the following table.

The methods and frequency of stakeholder involvement vary according to the issues and opportunities subject to discussion during the year.

Stevanato Group adopts practices that encourage dialogue and involvement with internal and external stakeholder categories as reported in this table:

Stakeholder Engagement and Interaction Flow

Stevanato Group Sustainability Economic Value Innovation Human Capital Supply Chain Environment Local Communities

Legal Entity (Country)2

ISO 15378

ISO 13485

ISO 9001

ISO 45001

ISO 14001

ISO 50001

Nuova Ompi (IT-PD)

✓

Nuova Ompi (IT-LT)

✓

Nuova Ompi (IT-Cisterna)

✓

Medical Glass (SK)

✓

Ompi North America (MX)

✓

Ompi of China (CN)

✓

Ompi do Brasil (BR)

✓

Balda Medical (DE)

✓

Ompi of America (U.S.)

✓

2 Legal Entities: Stevanato Group S.P.A., Nuova Ompi S.R.L., Medical Glass A.S., Ompi N. A. S. DE R. L. DE C. V., Ompi Do Brasil Indústria e Comércio de Embalagens Farmacêuticas LTDA, Ompi Pharmaceutical Packing Technology (China) CO., LTD., Ompi of America INC., Balda Medical GMBH, Balda/C. Brewer, S.P.A.M.I. S.R.L., Stevanato Group Denmark A/S, US TEC - Ompi of America INC., EMEA TEC - Nuova Ompi S.R.L. and EMEA TEC Analytics - Nuova Ompi S.R.L.

ISO 15378

Primary packaging material for medicine products - specific requirements for the application of ISO 9001:2015 with reference to Good Manufacturing Practice (GMP)

ISO 13485

Medical devices - Quality Management Systems

ISO 9001

Quality Management Systems

ISO 45001

Occupational Health and Safety Management System

ISO 14001

Environmental Management Systems

ISO 50001

Energy Management Systems

Stevanato Group Sustainability Economic Value Innovation Human Capital Supply Chain Environment Local Communities

Legal Entity (Country)2

ISO 15378

ISO 13485

ISO 9001

ISO 45001

ISO 14001

ISO 50001

Balda C. Brewer (CA-U.S.)

✓

EMEA TEC (IT), U.S. TEC (U.S.)

✓

Spami (IT)

✓

SG Denmark (DK)

✓

In 2025, Stevanato Group has been awarded the prestigious EcoVadis Silver Medal, reaching the outstanding score of 75/100. This places the Company in the top 15% of all companies assessed, just a few steps away from the Gold Medal-since Stevanato is ranked in the 92nd percentile.

EcoVadis is a globally recognized organization that evaluates companies based on their ESG performance.

Stevanato Group Sustainability Economic Value Innovation Human Capital Supply Chain Environment Local Communities

Stevanato Group participates in initiatives organized by trade associations and organizations, facilitating the exchange of ideas and knowledge.

In 2025, Stevanato did not participate in any

political-related and lobbying activities, and Stevanato had no monetary contributions to political-related and lobbying groups.

Stevanato Group Sustainability Economic Value Innovation Human Capital Supply Chain Environment Local Communities‌

Direct economic value generated and distributed (€/000) [GRI 201-1]

2025

2024

(A) Total economic value generated by Stevanato Group

1,191,776

1,126,623

(B) Economic value distributed by Stevanato Group

959,886

926,445

Operating costs - remuneration to suppliers

572,093

560,371

Remuneration to personnel

331,279

309,015

Remuneration to lenders

6,944

14,349

Remuneration of the public administration

49,275

42,552

Donations

296

189

(A-B) Economic value retained by Stevanato Group

231,889

200,177

Amortization & depreciation

87,345

78,036

Loss on receivable

1,221

2,616

Provisions and reserves

3,492

1,758

Net profit

139,831

117,766

The creation and distribution of direct economic value produced by

Stevanato Group and the impact on key stakeholder categories.

This section, reported on an accrual basis, includes

the basic components of Profit and Loss (P&L) statements for global Group operations in accordance with

GRI disclosure.

Stevanato's operational activities create value for a wide variety of stakeholders, including the following:

Suppliers (operating costs)

Personnel (employee wages and benefits as total payroll)

Lenders (financial charges)

Public administration (such as taxes)

Communities (e.g., donations)

In 2025, the economic value distributed by Stevanato Group totaled €960 million.

The difference between the value created and distributed was €232 million.

Stevanato Group Sustainability Economic Value Innovation Human Capital Supply Chain Environment Local Communities‌

Stevanato Group serves the pharma value chain with its two business segments:

the Biopharmaceutical and Diagnostic Solutions, and Engineering. For a detailed representation of the Group offering, please refer to Chapter 1.

Stevanato Group refers to the premium products in the biopharmaceutical and diagnostic solutions segment as its high-value solutions. High-value solutions are products, processes, and services for which the Group holds intellectual property rights or has strong proprietary

know-how, and they are characterized by technological and procedural complexity and high performance.

High-value solutions can deliver significant benefits to customers in terms of performance, including faster time to market, reduced total cost of ownership, and lower supply chain risk while providing added value to customers, and improving patient treatment and safety.

Stevanato Group Sustainability Economic Value Innovation Human Capital Supply Chain Environment Local Communities

• Biopharmaceutical and Diagnostic Solutions

Drug Containment Solutions

Stevanato Group has a vast range of commercially available drug containment solutions geared toward specific biopharmaceutical requirements.

Using the EZ-fill® pre-sterilized platform, the Group can streamline its customers' operations, reduce complexity in the aseptic filling process, and improve quality, allowing a reduction of the total cost of ownership.

The EZ-fill® configuration is available across all the product performance levels included in the Company's Drug Containment Solutions portfolio.

A summary overview of the main performance levels is provided in the figure to the right:

Stevanato Group Sustainability Economic Value Innovation Human Capital Supply Chain Environment Local Communities

Drug Delivery Systems

In recent years, Stevanato Group has strategically expanded its Drug Delivery Systems (DDS) offerings to include capabilities and services as an integrated solutions provider.

The Company is well positioned to help its pharmaceutical partners commercially launch drug products with a delivery device that meets the needs of patients. Stevanato Group focuses

on two main areas with regard to DDS: contract manufacturing and proprietary and licensed devices. Through contract manufacturing, Stevanato Group provides customers with scalable manufacturing solutions for their Drug Delivery System programs.

Customers can rely on the following:

Proprietary and licensed devices include pen injectors, autoinjectors, and on-body delivery systems.

Stevanato Group Sustainability Economic Value Innovation Human Capital Supply Chain Environment Local Communities

IVD Solutions

As a one-stop solution provider and manufacturer, the Group offers an integrated process, from process development to delivery of the final product, packaged, and sterilized as needed, including point-of-care devices and in-vitro diagnostic consumables.

Analytical & Testing Services

As a branch of research and development, Stevanato Group Technology Excellence Centers (TECs) focus on the following:

investigating the physical-chemical properties of primary packaging materials and components and studying the interactions between drug containment solutions and injectable drug products;

providing laboratory services for engineering characterization and design verification of pharmaceutical packaging, medical devices, and components comprising

combination products;

supporting customers in screening and selecting the most suitable container system solution for their injectable drug product platforms.

Stevanato Group relies on a multidisciplinary team of highly skilled scientists. Their knowledge and experience cover a range of specialized areas, including drug containment solutions and drug delivery devices.

• Engineering

Stevanato Group's vast portfolio of technologies and equipment includes state-of-the-art solutions for life science companies.

The Group specializes in fully automated glass-converting machines that are suitable for transforming glass tubes into vials, cartridges, syringes, and ampules.

The Group also provides flexible visual inspection solutions for containers filled with any drug, from transparent drugs to suspensions, and from liquid to gels, powders, or lyophilized drugs. Its portfolio ranges from benchtop to semiautomated and fully automatic equipment.

Stevanato Group designs and manufactures medical-device assembly and packaging equipment suitable for various stages, from device characterization with small-scale production to high-speed commercial assembly and packaging solutions. The technology is suitable for pen injectors, autoinjectors, wearable devices, and nasal sprays, and it includes packaging solutions for cartoning, case packing, and palletizing modules, with integrated serialization and tamper-evident units compliant with the latest requirements.

All Stevanato Group equipment in operation is supported by a global after-sales organization: a 24/7 support service that ensures continuous assistance to help customers resume production promptly as needed. Customer productivity is a top priority, and we offer a team of support specialists who are available to provide expert troubleshooting assistance in different areas of support: mechanical, electrical, automation, and vision.

Stevanato Group also supports customers with a comprehensive portfolio of services, including training, production support, and maintenance assistance, as well as products, such as spare parts and retrofit kits, enabling them to manage the entire life cycle of their equipment efficiently.

Stevanato Group Sustainability Economic Value Innovation Human Capital Supply Chain Environment Local Communities

Stevanato Group believes that one of its greatest challenges and opportunities ahead is to continue growing and supporting its customers through regenerative business innovation while making a positive impact that benefits all.

Investment in research and development is a fundamental component of Stevanato Group's growth and continued success, as reported in 2025 Annual 20-F Filing.

The R&D department operates in close collaboration with Stevanato Group's business segments to enable cross-functional integration and maximize value creation across the product life cycle. The R&D strategy is structured around three fundamental pillars that define priorities, guide technology development, and ensure alignment with the Company's

long-term growth strategy. These pillars represent the reference framework for all Group R&D divisions, with each R&D initiative explicitly mapped to one or more pillars to ensure strategic coherence and measurable impact.

With respect to product innovation and development, Stevanato Group systematically integrates sustainability principles into its R&D programs, starting from the earliest phases of development. Sustainability considerations are embedded in the technical requirements defined at project initiation and translated into design inputs for engineering activities.

This approach ensures that material selection, product architecture, and manufacturing concepts are evaluated and optimized with sustainability objectives in mind from the outset, rather than as downstream design constraints.

Stevanato Group Sustainability Economic Value Innovation Human Capital Supply Chain Environment Local Communities

• R&D for Drug Containment Solutions (DCS)

Stevanato Group's DCS team is dedicated to designing, developing, and manufacturing syringes, vials, and cartridges that provide higher drug compatibility between the primary packaging and the drug products (i.e., with the lowest particle generation, reduced, or even no extractable release, and metal-free options). The Drug Containment Solutions are offered in standard bulk or pre-sterilized, ready-to-use formats. The team is also responsible for the identification and development of Stevanato Group solutions for biologics needs, such as GLP-1s, mAbs, ADCs, and RNA-based drugs.

The DCS team strives to ensure compatibility between our primary packaging and the Group's proprietary and licensed devices, as well as the devices selected from customers, through appropriate testing and proper applicability of the Drug Delivery Systems to the glass primary packaging technical requirements specifications.

Stevanato Group has also introduced new sustainability practices as part of its corporate sustainability and circular innovation measures, with an emphasis on identifying alternative materials and processes that provide more sustainable sterilization techniques while maintaining the overall performance of the materials post-sterilization cycle.

As part of its corporate sustainability and circular innovation measures, Stevanato Group regularly dialogues with customers on a sustainable version of secondary packaging focused on biopolymers and recycled plastic as well as packaging and process improvements to reduce related emissions and other sustainable measures. Stevanato Group aims to reduce emissions and the use of fossil resources. Ready-to-use drug containers require single-use polymers for pharmaceutical secondary packaging (Nest and Tub) to help ensure sterility and processability. Indeed, a biocircular version of polystyrene and polypropylene that is used to produce secondary packaging of syringes has been identified. The raw material for producing

polymers is obtained from renewably sourced feedstocks derived solely from waste. This reduces fossil resource consumption and emissions associated with the life cycle of the product while ensuring the same level of quality. Hence, Stevanato Group could be International Sustainability and Carbon Certification (ISCC+) ready, as in the past, in

compliance with the mass balance approach, which helps maintain trust among customers and throughout the value chain.

The Group remains committed to innovation, and Stevanato Group's next-generation EZ-fill Smart® is expected to offer low-temperature vaporized hydrogen peroxide (VHP) sterilization, a more environmentally friendly method than traditional ethylene oxide (EtO) sterilization, which can result in improved safety. It is intended to improve sustainability and increase packaging efficiency using biopolymers and recycled plastic.

Over the past few years, Stevanato Group has concluded the Life Cycle Assessment (LCA) of some of its DCS product platforms. This rigorous process plays a pivotal role in making informed, data-driven decisions aimed at reducing the environmental impact of products. By pinpointing critical areas and designing future processes, the Group can quantify the potential benefits of sustainability initiatives and select the most promising ones.

In addition, Stevanato Group investigated how to reduce the environmental impact of glass-based end-of-life Drug Containment Solutions while identifying improved circular end-of-life solutions and creating upcycling solutions for glass-based products. In the past, Stevanato Group won first prize in an open innovation competition. The Company's R&D department partners with the regulatory department to assess the impact of the Plastic Packaging Waste Regulation on the existing product portfolio and on the new products

to be developed.

Disclaimer

Stevanato Group S.p.A. published this content on April 27, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 27, 2026 at 09:14 UTC.